Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT06234878 · ClinicalTrials.gov registry record · NA
REEV SENSE for Gait Analysis in Post-stroke Gait Impairment (SENS-AG)
A NA study of Stroke and Gait Disorders, Neurologic, sponsored by REEV.
- Completed
- Registry status
- NA
- Development phase
- 23
- Enrollment target
- 1
- Study location
NCT06234878: Completed NA study of Stroke and Gait Disorders, Neurologic, sponsored by REEV.
NCT06234878 is a NA study of Stroke and Gait Disorders, Neurologic that has completed, run by REEV. The registered enrollment target is 23 participants, below the 12,016-participant average among 454 other Stroke trials with a reported enrollment target (100% lower). The trial reports 1 study location across 1 state. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT06234878, a NA study of Stroke and Gait Disorders, Neurologic, has completed, sponsored by REEV.
- COMPLETED
- Registry status
- NA
- Development phase
- 23 participants
- Enrollment target
- 1
- Study location
Study Summary
The purpose of this study is to evaluate the clinical performance of the investigational REEV SENSE gait tracker to measure gait features in subjects with post-stroke gait impairment. REEV SENSE is intended to be used by trained healthcare professionals as a simple procedure adapted to clinical routine. The reference method for performance comparison will be motion capture.
Primary Outcome
Comparison of walking speed measured with REEV SENSE with reference method
Conditions Studied
Interventions
- DEVICE REEV SENSE
- DEVICE Motion capture system
Study Locations (1)
Massachusetts
- MIT Center for Clinical and Translational Research - Cambridge
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 23 participants |
| Start Date | 2024-01-08 |
| Est. Completion | 2025-04-01 |
| Phase | NA |
What the finished NCT06234878 record still lists
NCT06234878 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 23 participants, a relatively small participant target, below the 12,016-participant average among 454 other Stroke trials with a reported enrollment target (100% lower).
The record links to 2 conditions, with Stroke appearing as the primary indexed condition, and to 2 interventions - of which REEV SENSE is the first listed.
NCT06234878 reports a single indexed study location in Massachusetts.
Frequently Asked Questions
What is clinical trial NCT06234878 about?
NCT06234878 is a clinical study titled "REEV SENSE for Gait Analysis in Post-stroke Gait Impairment (SENS-AG)". The purpose of this study is to evaluate the clinical performance of the investigational REEV SENSE gait tracker to measure gait features in subjects with post-stroke gait impairment. REEV SENSE is intended to be used by trained healthcare professionals as a simple procedure adapted to clinical rou...
What is the current status of trial NCT06234878?
This trial is currently completed. It is a NA study. The enrollment target is 23 participants. The study started on 2024-01-08. Estimated completion is 2025-04-01.
What conditions does trial NCT06234878 study?
This clinical trial studies the following conditions: Stroke, Gait Disorders, Neurologic.
What interventions are being tested in trial NCT06234878?
The interventions under investigation include: REEV SENSE (DEVICE), Motion capture system (DEVICE).
Who is sponsoring clinical trial NCT06234878?
This trial is sponsored by REEV, which has 1 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT06234878 being conducted?
This trial has 1 study location across Massachusetts. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Stroke
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT06234878's enrollment target sits among peer trials
23 347th of 454 higher than 104 of 454 other Stroke trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Stroke trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
Tracking a Tactile Signal Along the Nervous System
RECRUITING · NA
-
Transcranial Direct Current Stimulation (tDCS) With Verb Network Strengthening Treatment (VNeST) in Chronic Aphasia
RECRUITING · NA
-
Strategy Training for Individuals With Unilateral Neglect
RECRUITING · NA
-
Weight Loss and ExeRcise
RECRUITING · NA
-
Safety and Feasibility of an ExoNET for Supination Assistance for Stroke Survivors
RECRUITING · NA
-
Deep Brain Stimulation Motor Ventral Thalamus (VOP/VIM) for Restoration of Speech and Upper-limb Function in People With Subcortical Stroke
RECRUITING · NA
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT03616041 · 23 participants
Capsule Endoscopy for Severe Hematochezia
- NCT04348747 · 23 participants · Phase 2
Dendritic Cell Vaccines Against Her2/Her3 and Pembrolizumab for the Treatment of Brain Metastasis From Triple Negative Breast Cancer or HER2+ Breast Cancer
- NCT04587687 · 23 participants · Phase 2
Brentuximab Vedotin and Bendamustine for the Treatment of Relapsed or Refractory Follicular Lymphoma
- NCT04715022 · 23 participants · Phase 1
Sympathetic-vascular Dysfunction in Obesity and Insulin Resistance (Vitamin C Study)
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI